PFIZER Back-Up Manufacturing Facilities Sample Clauses

PFIZER Back-Up Manufacturing Facilities. If, after approval of an NDA for a Product, additional back-up manufacturing facilities are required, PFIZER shall have the option, at its sole cost and expense, to request XXXXXX-XXXXXXX to file a supplement to have one or more of PFIZER's or any of its Affiliate's manufacturing facilities (the "PFIZER Facilities") qualified and approved as back-up manufacturing facilities. If PFIZER desires to have any of its facilities so qualified, PFIZER shall notify XXXXXX-XXXXXXX of the identity of such PFIZER Facilities and the back-up manufacturing services to be provided promptly after PFIZER has made this determination. XXXXXX-XXXXXXX shall have the right to visit and audit such PFIZER Facilities and review all other appropriate technical information to determine whether such PFIZER Facilities are acceptable, such consent not to be unreasonably withheld. If approved by XXXXXX-XXXXXXX, XXXXXX-XXXXXXX shall have the right to provide reasonable technical assistance in the qualification and approval of such PFIZER Facilities at the cost and expense of PFIZER. XXXXXX-XXXXXXX shall be solely responsible for filing all submissions or other correspondence with the FDA and/or other Governmental or Regulatory Authorities in connection with any decision to seek approval of a PFIZER Facility as an additional back-up manufacturing facility. XXXXXX-XXXXXXX shall also be responsible for determining technical and other conditions set forth in any supplement filed with reference to this Section. XXXXXX-XXXXXXX shall have the sole right to determine whether or not to use the PFIZER Facilities in the event of an interruption or depletion in supply of Product and, under such circumstances, a separate manufacturing agreement will be entered into between the parties.
Sample 1
AutoNDA by SimpleDocs

Related to PFIZER Back-Up Manufacturing Facilities

  • Joint Manufacturing Committee A joint manufacturing committee (the “Joint Manufacturing Committee” or “JMC”) will be established pursuant to the Supply Agreement. The roles and responsibilities of the JMC shall be as specified in the Supply Agreement.

  • Manufacturing Services Jabil will manufacture the Product in accordance with the Specifications and any applicable Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***].

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.

  • Manufacturing Intrexon shall have the option and, in the event it so elects, shall use Diligent Efforts, to perform any manufacturing activities in connection with the Aquaculture Program that relate to the Intrexon Materials, including through the use of a suitable Third Party contract manufacturer. To the extent that Intrexon so elects, Intrexon may request that AquaBounty and Intrexon establish and execute a separate manufacturing and supply agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials or bulk quantities of other components of AquaBounty Products, then Intrexon shall provide to AquaBounty or a contract manufacturer selected by AquaBounty and approved by Intrexon (such approval not to be unreasonably withheld) all Information Controlled by Intrexon that is (a) related to the manufacturing of such Intrexon Materials or bulk qualities of other components of AquaBounty Products for use in the Field and (b) reasonably necessary to enable AquaBounty or such contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials or bulk quantities of other components of AquaBounty Products. The costs and expenses incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to AquaBounty or its contract manufacturer shall not be further transferred to any Third Party, including any Product Sublicensee, or any AquaBounty Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit AquaBounty to switch manufacturers.

  • Development Plan As defined in Section 3.2(a).

  • Manufacturing Costs In the event of termination by Merck pursuant to Section 6.2, 6.3 or 6.6 above, Merck shall be entitled to [*****] (as defined herein) incurred by Merck for its Compound Delivered for the Study. [*****]

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Manufacturing Rights Manufacturing Rights will be governed by Attachment 6.

  • Project Plan Based on the Project Specifications, Omnicare CR has provided a description of services to be performed for Sponsor’s “A multi-center, randomized, double-blind, double-dummy, vehicle-controlled sequential cohort study to determine the safety of PEP005 0.025% and 0.05% topical gel in patients with actinic keratoses” (hereinafter “the Project”) and associated costs. Changes made in the Project scope, at any time during the Project, will result in a corresponding adjustment to the Project costs.

Time is Money Join Law Insider Premium to draft better contracts faster.